mRNA-3704
Phase 2Withdrawn 0 views this week 0 watching
0
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Methylmalonic Acidemia (MMA), Metabolism, Inborn Errors
Conditions
Methylmalonic Acidemia (MMA), Metabolism, Inborn Errors
Trial Timeline
May 28, 2019 → Aug 18, 2020
NCT ID
NCT03810690About mRNA-3704
mRNA-3704 is a phase 2 stage product being developed by Moderna for Methylmalonic Acidemia (MMA), Metabolism, Inborn Errors. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT03810690. Target conditions include Methylmalonic Acidemia (MMA), Metabolism, Inborn Errors.
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03810690 | Phase 2 | Withdrawn |
Competing Products
4 competing products in Methylmalonic Acidemia (MMA), Metabolism, Inborn Errors
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| mRNA-3705 | Moderna | Phase 2 | 0 |
| "The MaP Study": Mapping the Patient Journey in MMA and PA | Moderna | Preclinical | 0 |
| mRNA-3705 | Moderna | Phase 2 | 0 |
| Carglumic Acid | Recordati | Pre-clinical | 30 |